Senseonics Holdings, Inc. Reports First Quarter 2019 Financial Results
GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology
company focused on the design, development and commercialization of a
long-term, implantable continuous glucose monitoring (CGM) system for
people with diabetes, today reported financial results for the quarter
ended March 31, 2019.
RECENT HIGHLIGHTS & ACCOMPLISHMENTS:
- First quarter 2019 revenue of $3.4 million
-
Launched Eversense Bridge Patient Access Program to expand Eversense
access for patients across the U.S. -
Received positive coverage decision for Eversense from Techniker, the
largest payor in Germany covering over 10 million lives -
Initiated Eversense CGM data integration with the Glooko platform to
provide patients and providers insights and actions for diabetes
management based on personal glucose profiles
“We are pleased with our progress this year, which is marked by
growing interest and support of Eversense from users, prescribers and
payors,” said Tim Goodnow, President and Chief Executive Officer of
Senseonics. “We are seeing meaningful growth in both covered lives and
new users through our European partners. In the U.S., the launch of the
Eversense Bridge Patient Access Program is simplifying the reimbursement
process for new patients and supporting their ability to act on the
interest we see across patients and providers. It is also enabling
additional opportunities to get in front of the largest national payors.
Through constructive experiences with these payors, we believe that we
will obtain additional positive coverage decisions in the future. We are
looking forward to building on this momentum.”
FIRST QUARTER 2019 RESULTS:
Revenue was $3.4 million for the first quarter of 2019 including
adjustments for the bridge program, compared to $2.9 million for the
first quarter of 2018.
First quarter 2019 gross profit decreased by $2.9 million year-over
year, to ($3.3) million. The decrease in gross profit was associated
with one-time component obsolescence due to product upgrades and product
expiry due to the timing of the extension of the company’s distribution
agreement with Roche.
First quarter 2019 sales and marketing expenses increased $9.4 million
year-over year, to $12.8 million. The increase in sales and marketing
expenses was primarily driven by the build out of the U.S. salesforce.
First quarter 2019 research and development expenses decreased $1.0
million year-over-year, to $7.1 million. The decrease in research and
development expenses was primarily driven by the completion of all
activities associated with the U.S. PMA Panel meeting for Eversense.
First quarter 2019 general and administrative expenses increased $2.5
million, year-over-year, to $6.5 million. The increase in general and
administrative expenses was primarily driven by an increase in
compensation, legal and other administrative expenses associated with
supporting operational growth.
Net loss was $29.4 million, or $0.17 per share, in the first quarter of
2019, compared to $22.3 million, or $0.16 per share, in the first
quarter of 2018.
As of March 31, 2019, cash and cash equivalents were $103.7 million and
outstanding indebtedness was $65.2 million.
2019 Financial Outlook
Revenue for full year 2019 is expected to be in the range of $25 to $30
million.
CONFERENCE CALL AND WEBCAST INFORMATION
Company management will host a conference call at 4:30 pm (Eastern Time)
today, May 9, 2019, to discuss these financial results and recent
business developments. This conference call can be accessed live by
telephone or through Senseonics’ website.
|
|
|
|||||
|
Live Teleconference Information: |
Live Webcast Information:
Visit http://www.senseonics.com |
|||||
A replay of the call can be accessed on Senseonics’ website http://www.senseonics.com
under “Investor
Relations.”
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformative glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. From its inception, Senseonics has been
advancing the integration of novel, fluorescence sensor technology with
smart wearable devices. The Eversense® CGM System received
PMA approval from the FDA for up to 90 days of continuous use and is
available in the United States. The Eversense® XL CGM System
received CE mark for up to 180 days of continuous use and is available
in Europe. For more information on Senseonics, please visit www.senseonics.com.
FORWARD LOOKING STATEMENTS
Any statements in this press release about future expectations, plans
and prospects for Senseonics, including statements about the potential
additional positive coverage decisions, the potential commercialization
of Eversense in additional markets, Senseonics’ projected revenue for
full year 2019, the ongoing commercialization of Eversense in the U.S.
and Eversense XL in Europe, growing patient and clinician demand for
Eversense, and the potential life-enhancing benefits Eversense offers
people with diabetes, and other statements containing the words
“believe,” “expect,” “intend,” “may,” “projects,” “will,” and similar
expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
uncertainties in the development and regulatory approval processes,
uncertainties inherent in the commercial launch and commercial expansion
of the product, and such other factors as are set forth in the risk
factors detailed in Senseonics’ Annual Report on Form 10-K for the year
ended December 31, 2018, Senseonics’ Quarterly Report on Form 10-Q for
the quarter ended March 31, 2019, and Senseonics’ other filings with the
SEC under the heading “Risk Factors.” In addition, the forward-looking
statements included in this press release represent Senseonics’ views as
of the date hereof. Senseonics anticipates that subsequent events and
developments will cause Senseonics’ views to change. However, while
Senseonics may elect to update these forward-looking statements at some
point in the future, Senseonics specifically disclaims any obligation to
do so except as required by law. These forward-looking statements should
not be relied upon as representing Senseonics’ views as of any date
subsequent to the date hereof.
| Senseonics Holdings, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in thousands, except share and per share data) | ||||||||
| March 31, | December 31, | |||||||
| 2019 | 2018 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 103,675 | $ | 136,793 | ||||
|
Accounts receivable (primarily from a related party) |
2,367 | 7,097 | ||||||
| Inventory, net | 14,370 | 10,231 | ||||||
| Prepaid expenses and other current assets | 4,698 | 3,985 | ||||||
| Total current assets | 125,110 | 158,106 | ||||||
| Deposits and other assets | 114 | 117 | ||||||
| Property and equipment, net | 2,046 | 1,750 | ||||||
| Right of use asset, building | 2,131 | — | ||||||
| Total assets | $ | 129,401 | $ | 159,973 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,274 | $ | 4,407 | ||||
| Accrued expenses and other current liabilities | 13,754 | 13,851 | ||||||
| Right of use liability, building, current portion | 431 | — | ||||||
| Deferred revenue | — | 628 | ||||||
| Term Loans, current portion | 10,000 | 10,000 | ||||||
| Total current liabilities | 27,459 | 28,886 | ||||||
| Term Loans, net of discount and current portion | 2,347 | 4,783 | ||||||
| 2023 Notes, net of discount | 36,949 | 36,103 | ||||||
| Derivative liability | 15,019 | 17,091 | ||||||
| Term Loans, accrued interest | 1,892 | 1,764 | ||||||
| Right of use liability, building, net of current portion | 1,791 | — | ||||||
| Other liabilities | — | 85 | ||||||
| Total liabilities | 85,457 | 88,712 | ||||||
| Stockholders’ equity: | ||||||||
|
Common stock, $0.001 par value per share; 450,000,000 shares |
177 | 177 | ||||||
| Additional paid-in capital | 430,926 | 428,878 | ||||||
| Accumulated deficit | (387,159 | ) | (357,794 | ) | ||||
| Total stockholders’ equity | 43,944 | 71,261 | ||||||
| Total liabilities and stockholders’ equity | $ | 129,401 | $ | 159,973 | ||||
| Senseonics Holdings, Inc. | ||||||||
|
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss |
||||||||
| (in thousands, except share and per share data) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2019 | 2018 | |||||||
| Revenue, primarily from a related party | $ | 3,423 | $ | 2,946 | ||||
| Cost of sales | 6,733 | 3,308 | ||||||
| Gross profit | (3,310 | ) | (362 | ) | ||||
| Expenses: | ||||||||
| Sales and marketing expenses | 12,834 | 3,441 | ||||||
| Research and development expenses | 7,108 | 8,113 | ||||||
| General and administrative expenses | 6,516 | 4,011 | ||||||
| Operating loss | (29,768 | ) | (15,927 | ) | ||||
| Other income (expense), net: | ||||||||
| Interest income | 627 | 184 | ||||||
| Interest expense | (2,034 | ) | (1,771 | ) | ||||
| Change in fair value of derivative liability | 2,072 | (4,847 | ) | |||||
| Other (expense) income | (262 | ) | 88 | |||||
| Total other income (expense), net | 403 | (6,346 | ) | |||||
| Net loss | (29,365 | ) | (22,273 | ) | ||||
| Total comprehensive loss | $ | (29,365 | ) | $ | (22,273 | ) | ||
| Basic and diluted net loss per common share | $ | (0.17 | ) | $ | (0.16 | ) | ||
| Basic and diluted weighted-average shares outstanding | 176,954,116 | 137,069,008 | ||||||
Contacts
INVESTOR CONTACT
Lynn Lewis or Philip Taylor
Investor
Relations
415-937-5406
Investors@senseonics.com
